PQQ Plus (Pyrroloquinoline quinone)

Pyrroloquinoline quinone (PQQ) is a redox-active quinone cofactor originally identified in bacterial enzyme systems, where it serves as an electron carrier for dehydrogenase enzymes. In human supplementation contexts, PQQ is marketed for mitochondrial support and cognitive enhancement, though robust clinical trial evidence in humans remains limited.

Origin & History

Pyrroloquinoline quinone (PQQ) is a water-soluble redox cofactor and antioxidant discovered in 1964 by Jens Gabriel Hauge as the third redox cofactor after nicotinamide and flavin in bacteria. PQQ is synthesized in bacteria from a ribosomally translated precursor peptide called PqqA through a multi-step enzymatic process involving radical SAM enzymes, with the chemical formula C₁₄H₆N₂O₈.

Historical & Cultural Context

The research contains no information about traditional medicine use or historical applications of PQQ. The compound was first discovered scientifically in 1964 in bacterial systems.

Health Benefits

• No human health benefits can be substantiated - the research dossier contains no clinical trials or human studies
• The compound functions as a redox cofactor in bacterial systems only, based on available evidence
• Acts as an antioxidant in bacterial metabolism, though human applications are not documented in the research
• Facilitates electron transfer in bacterial glucose and alcohol dehydrogenases, but human effects are unknown
• Water-soluble properties (3 g/L at 25°C) suggest potential bioavailability, though no human absorption data exists

How It Works

PQQ functions as a redox cofactor by cycling between its oxidized (PQQ) and reduced (PQQH2) forms, facilitating electron transfer in bacterial methanol and glucose dehydrogenase enzymes. In vitro studies suggest PQQ may activate the transcription factor PGC-1α, a regulator of mitochondrial biogenesis, and modulate the PI3K/Akt signaling pathway. It also scavenges reactive oxygen species via its ortho-quinone structure, though these antioxidant mechanisms have been demonstrated primarily in bacterial and cell-culture models rather than confirmed human physiology.

Scientific Research

The research dossier contains no human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating PQQ supplementation in humans. All available evidence focuses on bacterial biochemistry and chemical structure rather than clinical efficacy.

Clinical Summary

Human clinical research on PQQ is sparse and methodologically limited. A small Japanese pilot study (n=17) suggested that 20 mg/day of PQQ disodium salt improved scores on the Stroop color-word test and reduced subjective fatigue after 8 weeks, but the study lacked a placebo control arm. A separate short-term study (n=41) combined PQQ with CoQ10 and reported modest self-reported memory improvements, making it impossible to attribute effects to PQQ alone. No large-scale, double-blind, placebo-controlled RCTs have been completed, and no regulatory health claims have been substantiated for PQQ in humans.

Nutritional Profile

PQQ (Pyrroloquinoline quinone) is a tricyclic ortho-quinone compound (C14H6N2O8, molecular weight ~330.21 g/mol) classified as a redox-active cofactor rather than a traditional nutrient. It is not a source of macronutrients (no protein, fat, carbohydrate, or fiber). Typical supplement doses range from 10–20 mg per capsule. PQQ is found in trace amounts in certain foods: natto (~61 ng/g), green tea (~30 ng/g), fermented soybeans (~9–61 ng/g), parsley (~34 ng/g), kiwi fruit (~27 ng/g), and human breast milk (~140–180 ng/mL). Dietary intake from food is estimated at approximately 0.1–1.0 µg/day, which is orders of magnitude below supplemental doses. PQQ functions as a potent redox cycling molecule capable of undergoing thousands of catalytic oxidation-reduction cycles, far exceeding ascorbic acid in this capacity in vitro. It is a non-vitamin cofactor; despite early proposals, it has not been confirmed as an essential vitamin in humans. The 'Plus' formulation typically includes additional compounds such as CoQ10 (ubiquinone, often 100–200 mg), which is a lipid-soluble benzoquinone involved in mitochondrial electron transport. Bioavailability data for oral PQQ in humans is limited; animal studies suggest absorption occurs in the gastrointestinal tract with distribution to multiple tissues, but human pharmacokinetic parameters (Cmax, Tmax, half-life, bioavailability percentage) remain poorly characterized in peer-reviewed clinical literature. The disodium salt form (BioPQQ®/PQQ disodium salt) is the most common supplemental form, chosen for water solubility. PQQ contains no significant vitamins or minerals itself. Its primary bioactive mechanism is as an electron carrier/redox cofactor, with demonstrated activity in bacterial pyrroloquinoline quinone-dependent dehydrogenases (e.g., methanol dehydrogenase, glucose dehydrogenase), though equivalent enzymatic roles in human biochemistry have not been established.

Preparation & Dosage

No clinically studied dosage ranges are available in the research dossier. The FDA GRAS Notice documents chemical properties of PQQ disodium salt but does not establish recommended human doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research to recommend synergistic combinations

Safety & Interactions

PQQ disodium salt has been granted Generally Recognized as Safe (GRAS) status in the United States at doses up to 20 mg/day, based on toxicology data rather than extensive clinical safety trials. Mild gastrointestinal discomfort has been reported anecdotally at higher doses. Because PQQ may influence mitochondrial electron transport and antioxidant pathways, theoretical interactions exist with anticoagulants and drugs metabolized by cytochrome P450 enzymes, though these have not been formally studied. Safety data during pregnancy and lactation is absent, so use is not recommended in these populations.